Valsartan/hydrochlorothiazide

From WikiProjectMed
Jump to navigation Jump to search
Valsartan/hydrochlorothiazide
Combination of
ValsartanAngiotensin II receptor antagonist
HydrochlorothiazideThiazide diuretic
Names
Trade namesCo-vasotec, Diovan HCT, Co-Diovan, others
Clinical data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
use		By mouth
Defined daily dosenot established[1]
External links
AHFS/Drugs.comFDA Professional Drug Information
MedlinePlusa611032
Legal
License data
Legal status

Lua error in Module:Sitelinks at line 59: attempt to index field 'results' (a nil value).


Valsartan/hydrochlorothiazide, sold under the trade name Co-Diovan among others, is an medication used to treat high blood pressure when valsartan is not sufficient.[2] It is a combination of valsartan, an angiotensin receptor blocker with hydrochlorothiazide, a diuretic.[3] It is taken by mouth.[3]

Common side effects include dizziness and headaches.[3] Serious side effects may include allergic reactions, electrolyte abnormalities, and glaucoma.[4] Use in pregnancy is not recommended.[4]

The combination was approved for medical use in the United States in 1998.[3] It is available as a generic medication.[2] A month supply in the United Kingdom costs the NHS about 1.85 as of 2019.[2] In the United States the wholesale cost of this amount is about US$4.40.[5] In 2017, it was the 133rd most commonly prescribed medication in the United States, with more than five million prescriptions.[6][7]

Dosage

The defined daily dose is not established[1]

Society and culture

Cost

A month supply in the United Kingdom costs the NHS about 1.85 as of 2019.[2] In the United States the wholesale cost of this amount is about US$4.40.[5] In 2017, it was the 133rd most commonly prescribed medication in the United States, with more than five million prescriptions.[7][6]

  • Hydrochlorothiazide/valsartan costs (US)

    Hydrochlorothiazide/valsartan costs (US)

  • Hydrochlorothiazide/valsartan prescriptions (US)

    Hydrochlorothiazide/valsartan prescriptions (US)

References

  1. ↑ 1.0 1.1 "WHOCC - ATC/DDD Index". www.whocc.no. Archived from the original on 1 July 2021. Retrieved 10 September 2020.
  2. ↑ 2.0 2.1 2.2 2.3 British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 179. ISBN 9780857113382.
  3. ↑ 3.0 3.1 3.2 3.3 "Hydrochlorothiazide and valsartan Uses, Side Effects & Warnings". Drugs.com. Archived from the original on 8 February 2018. Retrieved 10 March 2019.
  4. ↑ 4.0 4.1 "Valsartan and Hydrochlorothiazide - FDA prescribing information, side effects and uses". Drugs.com. Archived from the original on 16 July 2017. Retrieved 10 March 2019.
  5. ↑ 5.0 5.1 "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Archived from the original on 2019-03-06. Retrieved 3 March 2019.
  6. ↑ 6.0 6.1 "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
  7. ↑ 7.0 7.1 "Hydrochlorothiazide; Valsartan - Drug Usage Statistics". ClinCalc. Archived from the original on 11 April 2020. Retrieved 11 April 2020.

External links

Identifiers:


Stub icon

This drug article relating to the cardiovascular system is a stub. You can help MDWiki by expanding it.

Retrieved from "https://mdwiki.org/w/index.php?title=Valsartan/hydrochlorothiazide&oldid=1382668"